Year |
Citation |
Score |
2017 |
Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, ... Faivre E, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. PMID 28953875 DOI: 10.1038/Nature24028 |
0.306 |
|
2017 |
Lam LT, Lin X, Faivre EJ, Yang Z, Huang X, Wilcox DM, Bellin RJ, Jin S, Tahir SK, Mitten M, Magoc T, Bhathena A, Kati WM, Albert DH, Shen Y, et al. Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors. Molecular Cancer Therapeutics. PMID 28468776 DOI: 10.1158/1535-7163.MCT-16-0459 |
0.302 |
|
2016 |
Faivre EJ, Wilcox D, Lin X, Hessler P, Torrent M, He W, Uziel T, Albert DH, McDaniel K, Kati W, Shen Y. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. Molecular Cancer Research : McR. PMID 27707886 DOI: 10.1158/1541-7786.MCR-16-0221 |
0.325 |
|
2015 |
Suzawa M, Miranda DA, Ramos KA, Ang KK, Faivre EJ, Wilson CG, Caboni L, Arkin MR, Kim YS, Fletterick RJ, Diaz A, Schneekloth JS, Ingraham HA. A gene-expression screen identifies a non-toxic sumoylation inhibitor that Mimics SUMO-less human LRH-1 in liver. Elife. 4. PMID 26653140 DOI: 10.7554/Elife.09003 |
0.35 |
|
2011 |
Lee FY, Faivre EJ, Suzawa M, Lontok E, Ebert D, Cai F, Belsham DD, Ingraham HA. Eliminating SF-1 (NR5A1) sumoylation in vivo results in ectopic hedgehog signaling and disruption of endocrine development. Developmental Cell. 21: 315-27. PMID 21820362 DOI: 10.1016/J.Devcel.2011.06.028 |
0.428 |
|
2009 |
Hagan CR, Faivre EJ, Lange CA. Scaffolding actions of membrane-associated progesterone receptors. Steroids. 74: 568-72. PMID 19135465 DOI: 10.1016/J.Steroids.2008.12.004 |
0.703 |
|
2008 |
Campbell LA, Faivre EJ, Show MD, Ingraham JG, Flinders J, Gross JD, Ingraham HA. Decreased recognition of SUMO-sensitive target genes following modification of SF-1 (NR5A1). Molecular and Cellular Biology. 28: 7476-86. PMID 18838537 DOI: 10.1128/Mcb.00103-08 |
0.463 |
|
2008 |
Faivre EJ, Daniel AR, Hillard CJ, Lange CA. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Molecular Endocrinology (Baltimore, Md.). 22: 823-37. PMID 18202149 DOI: 10.1210/Me.2007-0437 |
0.777 |
|
2007 |
Daniel AR, Faivre EJ, Lange CA. Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 21: 2890-906. PMID 17717077 DOI: 10.1210/Me.2007-0248 |
0.782 |
|
2007 |
Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA. Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids. 72: 188-201. PMID 17173941 DOI: 10.1016/J.Steroids.2006.11.009 |
0.772 |
|
2007 |
Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Molecular and Cellular Biology. 27: 466-80. PMID 17074804 DOI: 10.1128/Mcb.01539-06 |
0.759 |
|
2005 |
Faivre E, Skildum A, Pierson-Mullany L, Lange CA. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids. 70: 418-26. PMID 15862825 DOI: 10.1016/J.Steroids.2005.02.012 |
0.768 |
|
2005 |
Zhang P, Ostrander JH, Faivre EJ, Olsen A, Fitzsimmons D, Lange CA. Regulated association of protein kinase B/Akt with breast tumor kinase. The Journal of Biological Chemistry. 280: 1982-91. PMID 15539407 DOI: 10.1074/Jbc.M412038200 |
0.728 |
|
2005 |
Skildum A, Faivre E, Lange CA. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Molecular Endocrinology (Baltimore, Md.). 19: 327-39. PMID 15486045 DOI: 10.1210/Me.2004-0306 |
0.756 |
|
2003 |
Pierson-Mullany LK, Skildum A, Faivre E, Lange CA. Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth. Breast Disease. 18: 21-31. PMID 15687686 DOI: 10.3233/Bd-2003-18104 |
0.764 |
|
2003 |
Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Molecular Endocrinology (Baltimore, Md.). 17: 628-42. PMID 12554776 DOI: 10.1210/Me.2002-0378 |
0.762 |
|
Low-probability matches (unlikely to be authored by this person) |
2020 |
Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, Zhang L, Bui MH, Sheppard GS, Wang L, Sehgal V, Lin X, Huang X, Lu X, Uziel T, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. PMID 31969702 DOI: 10.1038/s41586-020-1930-8 |
0.296 |
|
2015 |
Suzawa M, Miranda DA, Ramos KA, Ang KK, Faivre EJ, Wilson CG, Caboni L, Arkin MR, Kim Y, Fletterick RJ, Diaz A, Schneekloth JS, Ingraham HA. Author response: A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver Elife. DOI: 10.7554/Elife.09003.028 |
0.264 |
|
2017 |
Bui MH, Lin X, Albert DH, Li L, Lam LT, Faivre EJ, Warder S, Huang X, Wilcox D, Donawho CK, Sheppard GS, Wang L, Fidanze S, Pratt JK, Liu D, et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Research. PMID 28416490 DOI: 10.1158/0008-5472.CAN-16-1793 |
0.249 |
|
2021 |
Zhang L, Cai T, Lin X, Huang X, Bui MH, Plotnik JP, Bellin RJ, Faivre EJ, Kuruvilla VM, Lam LT, Lu X, Zha Z, Feng W, Hessler P, Uziel T, et al. Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia. Molecular Cancer Therapeutics. PMID 34253595 DOI: 10.1158/1535-7163.MCT-21-0029 |
0.237 |
|
2017 |
McDaniel KF, Wang L, Soltwedel T, Fidanze SD, Hasvold LA, Liu D, Mantei RA, Pratt JK, Sheppard GS, Bui MH, Faivre EJ, Huang X, Li L, Lin X, Wang R, et al. Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/mivebresib), a Potent and Orally Available Bromodomain and Extraterminal domain (BET) Family Bromodomain Inhibitor. Journal of Medicinal Chemistry. PMID 28949521 DOI: 10.1021/acs.jmedchem.7b00746 |
0.164 |
|
2018 |
Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, ... Faivre E, et al. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. PMID 29769713 DOI: 10.1038/S41586-018-0111-5 |
0.084 |
|
2020 |
Sheppard GS, Wang L, Fidanze SD, Hasvold LA, Liu D, Pratt JK, Park CH, Longenecker KL, Qiu W, Torrent M, Kovar P, Bui M, Faivre EJ, Huang X, Lin X, et al. Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain. Journal of Medicinal Chemistry. PMID 32324999 DOI: 10.1021/acs.jmedchem.0c00628 |
0.081 |
|
Hide low-probability matches. |